References
- Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol 2013;98:24–33. doi:10.1007/s12185-013-1384-y
- Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood J Am Soc Hematol. 2009;113(26):6511–6521.
- Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966
- Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:10.1182/bloodadvances.2019000812
- Mithoowani S, Arnold DM. First-line therapy for immune thrombocytopenia. Hämostaseologie. 2019;39(03):259–265. doi:10.1055/s-0039-1684031
- Park YH, Kim D-Y, Kim S, et al. Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. Blood Res. 2022;57(1):20–28. doi:10.5045/br.2022.2022043
- Cuker A, Prak ETL, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost 2015;41(4):395–404.
- Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016;3(10):e489–ee96. doi:10.1016/S2352-3026(16)30109-0
- Alharbi MG, Alanazi N, Yousef A, et al. COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis. Expert Rev Hematol. 2022;15(2):157–166. doi:10.1080/17474086.2022.2029699
- Lozano ML, Segú-Vergés C, Coma M, et al. Elucidating the mechanism of action of the attributed immunomodulatory role of eltrombopag in primary immune thrombocytopenia: an in silico approach. Int J Mol Sci. 2021;22(13):6907. doi:10.3390/ijms22136907
- Bussel JB, Soff G, Balduzzi A, et al. A review of romiplostim mechanism of action and clinical applicability. Drug Des Devel Ther. 2021;15:2243–2268.
- Markham A. Avatrombopag: a review in thrombocytopenia. Drugs. 2021;81:1905–1913.
- FDA. Eltrombopag full prescribing information; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207027s000lbl.pdf.
- EMA. Eltrombopag summary of product characteristics; 2023. Available from: https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf.
- FDA. Romiplostim full prescribing information; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125268s163lbl.pdf.
- EMA. Romiplostim summary of product characteristics; 2023. Available from: https://www.ema.europa.eu/en/documents/product-information/nplate-epar-product-information_en.pdf.
- FDA. Avatrombopag full prescribing information; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210238s001lbl.pdf.
- EMA. Avatrombopag summary of product characteristics; 2023. Available from: https://www.ema.europa.eu/en/documents/product-information/doptelet-epar-product-information_en.pdf.
- González-Porras JR, Godeau B, Carpenedo M. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719837906.
- Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735.
- NICE. Avatrombopag for treating primary chronic immune thrombocytopenia. Technology appraisal guidance [TA853]; 2022. Available from: https://www.nice.org.uk/guidance/ta853.
- Gilbert MM, Grimes AB, Kim TO, et al. Romiplostim for the treatment of immune thrombocytopenia: spotlight on patient acceptability and ease of use. Patient Prefer Adherence. 2020;14:1237–1250.
- Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol 2022;197(3):359–366. doi:10.1111/bjh.18081
- Cooper N, Hill QA, Grainger J, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel. Acta Haematol 2021;144(4):418–426. doi:10.1159/000510676
- Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol 2021;193(2):386–396. doi:10.1111/bjh.17334
- Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol 2021;96(2):188–198. doi:10.1002/ajh.26045
- McDonald V, Newland A, Morgan M, et al. Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study). Hematology. 2021;26(1):799–808. doi:10.1080/16078454.2021.1978689
- Efficace F, Mandelli F, Fazi P, et al. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am J Hematol 2016;91(10):995–1001. doi:10.1002/ajh.24463
- Tarantino MD, Mathias SD, Snyder CF, et al. Impact of ITP on physician visits and workplace productivity. Curr Med Res Opin. 2010;26(2):319–328. doi:10.1185/03007990903451298
- Lucchesi A, Lovrencic B, McDonald V, et al. Pcr246 patient preferences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in Italy (TRAPeze Italy study). Value Health. 2022;25(12):S437–S4S8.
- Nederland P. Patiëntenvereniging Nederland Homepage; 2023. Available from: https://www.itp-pv.nl/over-de-patientenvereniging.
- Database DG. Number of users 2017-2021 for ATC subgroup B02BX: Other systemic haemostatics; 2022. Available from: https://www.gipdatabank.nl/databank?infotype=g&label=00-totaal&tabel=B_01-basis&geg=gebr&item=B02BX.
- Rovó A, Cantoni N, Samii K, et al. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: results from a questionnaire conducted in Switzerland, Austria, and Belgium. Plos one. 2022;17(4):e0267342.
- Zwaginga JJ, van der Holt B, Te Boekhorst PA, et al. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica. 2015;100(3):e90. doi:10.3324/haematol.2014.110213
- Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–1123. doi:10.3324/haematol.2018.212845
- Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161(3):411–423. doi:10.1111/bjh.12260
- Kruse A, Kruse C, Potthast N, et al. Mental health and treatment in patients with immune thrombocytopenia (ITP); data from the Platelet Disorder Support Association (PDSA) Patient Registry. Blood. 2019;134:2362. doi:10.1182/blood-2019-122278
- Terrell DR, Reese J, Branesky D, et al. Depression in adult patients with primary immune thrombocytopenia. Am J Hematol 2016;91(10):E462–E4E3.
- Commission E. Labour market information: Netherlands; 2022. Available from: https://eures.ec.europa.eu/living-and-working/labour-market-information/labour-market-information-netherlands_en.
- Ruotolo I, Berardi A, Sellitto G, et al. Criterion validity and reliability of SF-12 health survey version 2 (SF-12v2) in a student population during COVID-19 pandemic: a cross-sectional study. Depress Res Treat. 2021;2021:1–10.
- Sanz MA, Aledort L, Mathias SD, et al. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health. 2011;14(1):90–96. doi:10.1016/j.jval.2010.10.017